Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Armata Pharmaceuticals, Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, which implies a level of consistency in the examination process for a portion of the portfolio. The 3 pending actions are further categorized into 2 distinct art units, reflecting a focused but slightly varied technical scope in the company's current filings.
SINGH, SATYENDRA K is the busiest examiner, overseeing 2 pending office actions. This concentration means that a majority of the company's active matters are subject to the scrutiny of a specific individual, while the other of the 2 distinct examiners handles the rest of the 3 pending office actions. This distribution suggests that the outcome of the 2 pending actions under SINGH, SATYENDRA K will be the primary driver of the portfolio's immediate progress.
The presence of 2 distinct art units indicates that the 3 pending office actions may involve different pharmaceutical sub-specialties. Practitioners should prioritize the 2 pending actions with SINGH, SATYENDRA K to maximize efficiency. The overall strategy must address the requirements of 2 distinct examiners to successfully clear the 3 pending office actions currently on the docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, SATYENDRA K | 2 | 61.5% | +67.9% |
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592379 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION | SINGH, SATYENDRA K | — |
| 18294138 | BACTERIOPHAGES WITH IMPROVED ANTIMICROBIAL ACTIVITY | WANG, RUIXUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917543 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION | SINGH, SATYENDRA K | 9d overdue |
| 18592379 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION | SINGH, SATYENDRA K | — |
| 18294138 | BACTERIOPHAGES WITH IMPROVED ANTIMICROBIAL ACTIVITY | WANG, RUIXUE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18592379 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION | SINGH, SATYENDRA K | 1657 | §101§103§112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18294138 | BACTERIOPHAGES WITH IMPROVED ANTIMICROBIAL ACTIVITY | WANG, RUIXUE | 1672 | §103§112 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 17917543 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION | SINGH, SATYENDRA K | 1657 | Other | Final Rejection | 9d overdue | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArmata Pharmaceuticals, Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Satyendra K Singh has the most, with 2 of Armata Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
